P4-035: THERAPEUTIC EFFECTS OF NOVEL TAU ANTIBODY

Anti-tau antibody reduces insoluble tau and decreases brain atrophy

OBJECTIVE We previously found a strong reduction in tau pathology and insoluble tau in P301S tau transgenic mice following intracerebroventricular infusion of the anti-tau antibody HJ8.5. We sought to determine the effects of HJ8.5 in the same model following peripheral administration. METHODS The primary objective was to determine if HJ8.5 administered at a dose of 50 mg kg(-1) week(-1) by i...

Wst 45.10 - 035

Continuous experiments were conducted to study the influence of pH in the range 4.0–6.5 on the acidification of dairy wastewater at 37°C with 12 hours of hydraulic retention in an upflow reactor. Results showed that degradation of dairy pollutants increased with pH from pH 4.0 to 5.5. At pH 5.5, 95% of carbohydrate, 82% of protein and 41% of lipid were degraded. Based on chemical oxygen demand ...

Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections.

Antibodies are potent components of the immune repertoire and have been successfully exploited to treat bacterial infections. Recently an antibody-antibiotic conjugate (AAC) that combines key attributes of an antibody and antibiotic has been shown to be efficacious against Staphylococcus aureus infection. An AAC has three components: an antibiotic payload to kill bacteria, an antibody to target...

Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

Alzheimer's disease is characterized by the deposition of amyloid-β as extracellular plaques and hyperphosphorylated tau as intracellular neurofibrillary tangles. Tau pathology characterizes not only Alzheimer's disease, but also many other tauopathies, presenting tau as an attractive therapeutic target. Passive tau immunotherapy has been previously explored; however, because only a small fract...

Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody